A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
Mycobacterium Avium-intracellulare Infection, HIV Infections
About this trial
This is an interventional treatment trial for Mycobacterium Avium-intracellulare Infection focused on measuring AIDS-Related Opportunistic Infections, Placebos, Mycobacterium avium-intracellulare Infection, Acquired Immunodeficiency Syndrome, Antitubercular Agents, Azithromycin, Drug Resistance, Microbial, CD4 Lymphocyte Count, Antibiotics, Time Factors, Anti-HIV Agents, Pneumonia, Bacterial, Streptococcus pneumoniae
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Have 2 CD4 counts over 100 cells/mm3 at least 30 days apart. Have a history of CD4 counts under 50 cells/mm3. Are at least 13 years old (need consent if under 18). Are in reasonably good health. Are expected to live for at least 6 months. Are receiving anti-HIV medications at study entry. Exclusion Criteria You will not be eligible for this study if you: Have/had MAC disease. Have been unable to take azithromycin in the past. Are on any medications that act against MAC.
Sites / Locations
- Community Consortium / Jon Kaiser Wellness Ctr
- Community Consortium / UCSF
- Denver CPCRA / Denver Public Hlth
- Washington Reg AIDS Prog / Dept of Infect Dis
- AIDS Research Consortium of Atlanta
- AIDS Research Alliance - Chicago
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
- LSMUC / Lions Clinic
- Catherine McAuley Health Ctr
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr
- Henry Ford Hosp
- Southern New Jersey AIDS Cln Trials / Dept of Med
- North Jersey Community Research Initiative
- Partners in Research / New Mexico
- Harlem AIDS Treatment Grp / Harlem Hosp Ctr
- The Research and Education Group
- Philadelphia FIGHT
- Saint Joseph's Hosp
- Richmond AIDS Consortium / Div of Infect Diseases